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Abstract Genome-wide Association Studies (GWAS)
revealed novel genetic markers for breast cancer suscepti-
bility. But little is known about the risk factors and molecular
events associated with breast cancer in Arab Population.
Therefore, we designed a broad study to investigate the
susceptibility and prognostic implications of the GWAS
breast cancer loci in the Tunisian population. In a cohort of
640 unrelated patients with breast cancer and 371 healthy
control subjects, we characterized the variation of 9 single
nucleotide polymorphisms (SNPs), namely rs1219648,
rs2981582; rs8051542, rs12443621, and rs3803662;
rs889312; rs3817198; rs13387042 and rs13281615. Only 5
out of 9 GWAS breast cancer loci were found to be signifi-
cantly associated with breast cancer in Tunisians: The
rs1219648 (G vs. A allele: OR = 1.36, P = 1 9 10-3) and
rs2981582 (A vs. G allele: OR = 1.55, P = 3 9 10-6) of
FGFR2 gene; the rs8051542 of the TNRC9 gene (T vs. C
allele: OR = 1.40, P = 4 9 10-4); the rs889312 of the
MAP3K1 gene (C vs. A allele: OR = 1.33, P = 3 9 10-3)
and the rs13281615 located on 8q24 (G vs. A allele:
OR = 1.21, P = 0.03). Homozygous variant genotypes of
rs2981582 were strongly related to lymph node negative
breast cancer (OR = 3.33, P = 6 9 10-7) and the minor
allele of rs2981582 was associated with increased risk of
ER? tumors (OR = 1.57, P = 0.02; OR = 2.15,
P = 0.001, for heterozygous and homozygous variant
genotypes, respectively) and increased risk of distant
metastasis development (OR = 2.30, P = 4 9 10-3;
OR = 3.57, P = 6 9 10-5, for heterozygous and homozy-
gous variant genotypes, respectively) in a dose dependent
manner. The association for rs8051542 was stronger for
high-grade SBR tumors (OR = 2.54, P = 2 9 10-4). GG
genotype of rs13387042 on 2q35 showed a significant
association with the risk of developing distant metastasis
(OR = 1.94, P = 0.02). The G allele of rs1219648 in
FGFR2 and the A allele of rs13387042 on 2q35 indicated a
better prognosis by showing a significantly higher overall
survival rates (P = 0.013 and P = 0.005, respectively).
In conclusion, GWAS breast cancer FGFR2, TNRC9,
MAP3K1, and 8q24 loci are associated with an increased risk
of breast cancer and genetic variation in FGFR2 gene may
predict the aggressiveness of breast cancer in Tunisians.
Keywords Breast cancer  Tunisians  Arabs  GWAS 
Prognosis  Survival
Introduction
Breast cancer is the most common form of malignancy
affecting women worldwide [1, 2]. Breast cancer
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incidence rates have increased progressively in Arab
populations over the last 10 years, probably due to more
reliable data being collected from cancer registries and to
easier access by patients screening and diagnostic pro-
gram [3]. In Arab populations, breast cancer represents
*13–30 % of newly diagnosed malignancies in women
and occurs at a median age of 49–52 years as compared
to 63 in industrialized nations [3]. It is characterized by
younger age at onset, advanced stage and poor prognosis
[3]. In Tunisia, breast cancer remains the most common
cancer among women, and it is considered to be a real
problem of public health. During the period from 1993 to
2007, the Cancer Registry of the Center of Tunisia
counted 2,404 new cases of breast cancer. The median
age at diagnosis was 48 years and the age-standardized
incidence rate (ASR) was 29.2 per 100,000 s during the
study period [4].
The etiology of breast cancer is extremely complex and,
while not yet elucidated, appears to involve numerous
genetic, endocrine, and external environmental factors.
Family history represents the most prominent risk factor
for the development of the disease. It is estimated that
about 5–10 % of all breast cancers may arise from the
inheritance of germline mutations in dominant highly
penetrant susceptibility genes such as BRCA1 and BRCA2.
Mutations in these genes are rare and explain only a small
fraction of the familial risk for the disease [5, 6]. This
leads to the suggestion that the remaining breast cancer
susceptibility is likely to be explained by a polygenic
model involving a combination of low-penetrance alleles,
each conferring a small increase in risk [7]. Recently,
genome-wide association studies (GWAS) have provided a
systematic way to search for genetic variants and have
successfully identified several low-penetrance susceptibil-
ity loci for breast cancer [8–19]. Most of breast cancer
GWAS and replications published today has been con-
ducted in Northern European populations [8–10, 12,
14–16, 18] and to a lesser extent in Asians [13, 17, 19] and
Ashkenazi Jews [11]. Thus, it is important to assess
whether these variants confer risk across different popu-
lations with diverse ancestry backgrounds, including
women of Arab ancestry. Moreover, little is known about
risk factors and molecular events associated with breast
cancer in Arab populations, which differ strongly from the
other populations by ethnicity, lifestyle, reproductive
behavior, and environmental exposure. This prompts us to
analyze the previously GWAS-identified breast cancer risk
variants in Tunisians using a case–control study. In this
report, we focus on nine polymorphisms in the following
genes/regions: FGFR2, TNRC9 (also known as TOX3),
MAP3K1, LSP1, 2q35, and 8q24. We further explored
other potential effects of these risk loci on disease char-
acteristics and survival.
Materials and methods
Study population
A total of 1,011 individuals, comprising 640 breast cancer
patients and 371 healthy controls, were included in this study.
Controls and patients were selected from the same population
living in the middle coast of Tunisia and including only
unrelated subjects. The sporadic breast cancer patients were
recruited from the department of Radiation Oncology of
Sousse Hospital (Sousse, Tunisia) between 1996 and 2011.
Their disease information was obtained from their hospital
medical records. All patients included in this study had pri-
mary breast cancer, with unilateral breast tumors and with no
family history of the disease. The diagnosis of cancer was
confirmed by histopathological analyses. The patients had a
mean age of 47.9 ± 10 years. The median follow-up was
65 months (range, 1–276 months). At the time of analysis,
118 patients relapsed (local or distant recurrence). Among
them, 20 (17 %) patients died from breast cancer. A detailed
description of the clinic-pathological characteristics of this
cohort was summarized in Table 1.
Controls were healthy women having a mean age of
55 ± 14 years. They were blood donors with no evidence
of any personal or family history of cancer (or other
chronic illness). Samples from healthy controls were col-
lected consecutively between 2004 and 2010 and were age
matched to the cases.
Both patients and controls gave their written consent to
participate in the study and to allow their biological sam-
ples to be genetically analyzed. Approval for the study was
given by the Tunisian National Ethical Committee and by
Weill Cornell Medical College in Qatar IRB committee.
Genomic DNA extraction
Genomic DNA was extracted from peripheral blood leuko-
cytes by a ‘‘salting out’’ procedure [20]. Briefly, 10 ml of blood
was mixed with Triton lysis buffer (0.32 M sucrose, 1 %
Triton X-100, 5 mM MgCl2, H2O, 10 mM Tris–HCl, pH 7.5).
Leukocytes were spun down and washed with H2O. The pellet
was incubated with proteinase K at 56 C and subsequently
salted out at 4 C using a saturated NaCl solution. Precipitated
proteins were removed by centrifugation. The DNA in super-
natant fluid was precipitated with ethanol. The DNA pellet was
dissolved in 400 ll of sterile distilled water. DNA concentra-
tion and quality were analyzed by the nanodrop 2000.
SNP selection and genotyping
We selected and genotyped 9 SNPs that had been associ-
ated with increased risk of breast cancer in GWAS studies.
This includes rs1219648 and rs2981582 in FGFR2.
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rs8051542, rs12443621 and rs3803662 in TNRC9,
rs889312 in MAP3K1, rs3817198 in LSP1, rs13387042 in
2q35 and rs13281615 in 8q24.
Genotyping was performed using the TaqMan SNP
genotyping assays. PCR mixture was as follows: 12.5 ll of
TaqMan 29 Universal PCR Master Mix, 5-25 ng of DNA,
0.625 ll of predesigned TaqMan SNP Genotyping Assay
mix (409) and water to bring the final reaction volume to
25 ll. The PCR thermal cycling was as follows: initial
denaturing at 95 C for 10 min; 40 cycles of 92 C for 15 s
and 60 C for 1 min. Thermal cycling was performed using
the Applied Biosystems 7500 Real-Time PCR System. All
reactions were carried out with no template as negative
controls. Genotype call success rate for cases and for controls
was 97.6 and 97.8 %, respectively. Randomly selected DNA
sequencing and PCR replication with a coincidence rate
greater than 99 % verified genotype reproducibility.
Statistical analyses
The genotype and allele frequencies of the 9 SNPs that had
been associated with increased risk of breast cancer in
GWAS were tested for the Hardy–Weinberg equilibrium for
both patient and control groups using the Chi-square test.
According to the general genotype model, risk association
between the genotypes and breast cancer susceptibility and
tumors characteristics was estimated by crude odds ratio
(OR) and 95 % confidence intervals (95 % CI) using the
unconditional logistic regression analysis with the low-risk
genotype as a reference category [21, 22]. A P value of less
than 0.05 was required for statistical significance.
Clinical pathological parameters were dichotomised as
follows: nodal status (C1 vs. no positive lymph node), SBR
(Scarff, Bloom and Richardson) tumor grade (1–2 vs. 3),
clinical tumor size (T1–T2 vs. T3–T4) and estrogen/pro-
gesterone receptor status (positive vs. negative).
The statistical analysis was performed using the Epi-
Info statistical program (version 5.01; Centers for disease
Control and Epidemiology Program office, Atlanta Geor-
gia, USA). Breast cancer-specific overall survival (OVS)
was defined as the time from the date of diagnosis to death
if the patient died from breast cancer or to last contact. Six-
year survival rates were estimated, and survival curves
were plotted according to Kaplan and Meier [23]. The
differences between groups were calculated by the log-rank
test [24]. Univariate analyses for each SNP were carried
out by estimating Kaplan–Meier survival curves stratified
by genotypes using SEM-STATISTIQUES software
(Centre Jean Perrin, Clermont-Ferrand, France).
Results
GWAS-identified loci as risk factors for breast cancer
in Tunisians
Minor allele frequencies and estimates for the association
between the nine SNPs and overall breast cancer risk are
shown in Table 2. Genotype frequencies in cases and
controls appear in Supplementary Table 1. Genotype dis-
tribution of all SNPs in both patients and controls did not
deviate from Hardy–Weinberg equilibrium (P [ 0.05)
(Supplementary Table 1).
In this study, 5 out of the 9 breast cancer-associated SNPs
discovered in GWAS were replicated in the Tunisian popu-
lation. Both polymorphisms of FGFR2 (rs1219648,
rs2981582), TNRC9 rs8051542, MAP3K1 rs889312, and the
SNP located on 8q24 (rs13281615) were statistically sig-
nificantly associated with breast cancer risk at P less than
0.05 (Table 2). A suggestive association was observed
between rs3817198 in LSP1 gene and breast cancer risk with
an increased risk for GG genotype and G allele (OR = 1.45,
P = 0.1; OR = 1.19, P = 0.08, respectively). However, no
significant evidence was observed for associations between
the two other SNPs in TNRC9 and the SNP located on 2q35
Table 1 Description of the study population
Characteristics Cases (%)
Sample size 640
Age range (year) 23–91
Age at diagnosis (mean ± SD) 47.9 ± 10
Menopausal status
Pre-menopausal 304 (53.1)
Post-menopausal 269 (46.9)
Tumor size
T1–T2 421 (71)
T3–T4 172 (29)
Lymph node involvement
Positive 367 (61)
Negative 235 (39)
Histological grade
SBR1-2 354 (62.9)
SBR3 209 (37.1)
Estrogen receptor (ER) status
Positive 202 (51.1)
Negative 193 (48.9)
Progesterone receptor (PR) status
Positive 167 (42.1)
Negative 230 (57.9)
ER/PR status
ER?/PR? 143 (36.2)
ER?/PR- 59 (14.9)
ER-/PR? 22 (5.6)
ER-/PR- 171 (43.3)
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and breast cancer risk (P = 0.49, 0.3 and 0.16 for
rs12443621, rs3803662, and rs13387042, respectively).
Most significant associations were of high magnitude.
The strongest associations were found for rs2981582 in the
FGFR2 gene and rs8051542 in the TNRC9 gene. Homo-
zygous variant genotypes of rs2981582 and rs8051542
were associated with over a two-fold increased risk of
breast cancer (OR = 2.23, P = 0.00001; OR = 2.11,
P = 0.0001, respectively).
Effects of GWAS risk loci on disease characteristics
of breast cancer
In this study, we also analyzed the effects of the 9 GWAS-
identified SNPs on a series of disease clinico-pathological
characteristics, including clinical tumor size, SBR tumor
grade, lymph node metastasis, distant metastasis, and
estrogen/progesterone receptor status.
Both polymorphisms of the FGFR2 gene and rs8051542
in the TNRC9 gene were found to be associated with either
small or large clinical tumor size. However, slightly
stronger associations were found for FGFR2 rs2981582
and TNRC9 rs8051542 with T1–T2 tumor size
(P = 0.0001, P = 0.0002, respectively) (Supplementary
Table 2). Variant allele of rs889312 in the MAP3K1 gene
seems to be associated with increased risk of both small
and large tumors (OR = 1.70, P = 0.03; OR = 1.89,
P = 0.04) (Supplementary Table 2). However, homozy-
gous variant genotype of rs13281615 on 8q24 was found to
be associated with increased risk of small tumor size
(OR = 1.63, P = 0.01).
For homozygous variant genotypes of both polymor-
phisms in the FGFR2 gene, the associations were also
stronger with low than with high-grade SBR (OR = 2.01,
P = 0.0008 for rs1219648; OR = 2.53, P = 0.00001 for
rs2981582) (Supplementary Table 3). However, stronger
association with high-grade SBR was found for rs8051542
in the TNRC9 gene (OR = 2.54, P = 0.0002) (Supple-
mentary Table 3).
Associations of both polymorphisms in the FGFR2 gene
(rs1219648 and rs2981582) with breast cancer risk were
stronger for patients with negative than with positive nodal
involvement. The strongest association was found with
rs2981582. Homozygous variant genotype was associated
with over threefold increased risk of lymph node negative
breast cancer (OR = 3.33, P = 0.0000006) (Table 3). For
both polymorphisms, increased breast cancer risk with
negative nodal involvement was associated with the minor
allele in a dose-dependant manner. Moreover, among
cases, rs2981582 AA genotype was more frequent in
lymph node negative compared to lymph node positive
breast cancers (28.5 vs. 21.9 %; OR = 0.56, P = 0.018)
(Table 3). The association of rs8051542 in the TNRC9
gene with breast cancer risk tended to be slightly stronger
for patients with positive nodal involvement (OR = 2.15,
P = 0.0004) (Table 3). However, rs889312 in the
MAP3K1 gene was equally associated with lymph node
negative and positive breast cancer (Table 3).
Associations by ER and PR tumor status revealed also
some findings. Stratification of tumors by ER status indi-
cated that rs2981582 FGFR2 polymorphism increased risk
of both ER? and ER- tumors. Slightly stronger association
was observed with ER? (P = 0.001, P = 0.01 for ER? and
ER-, respectively) (Supplementary Table 4). Moreover, the
minor allele was associated with increased risk of ER?
tumors in a dose-dependant manner (OR = 1.57, P = 0.02;
Table 2 Association of nine SNPs identified from previous GWAS with breast cancer risk in Tunisian women
SNP Gene/
locus
Allelea Risk allele
Frequency (%)
HetOR
(95 % CI)
P value HomOR
(95 % CI)
P value Per risk allele
(95 % CI)
P value
Case Control
rs1219648 FGFR2 A/G 45.7 38.2 1.60 (1.19–2.16) 0.001 1.70 (1.15–2.51) 0.004 1.36 (1.13–1.65) 0.001
rs2981582 FGFR2 G/A 50.2 39.4 2.00 (1.47–2.73) 0.000004 2.23 (1.51–3.29) 0.00001 1.55 (1.28–1.88) 0.000003
rs8051542 TNRC9b C/T 44.5 36.4 1.15 (0.86–1.54) 0.32 2.11 (1.39–3.19) 0.0001 1.40 (1.16–1.69) 0.0004
rs12443621 TNRC9 G/A 46.6 48.2 0.86 (0.63–1.18) 0.34 0.89 (0.61–1.30) 0.53 0.94 (0.78–1.13) 0.49
rs3803662 TNRC9 C/T 45.9 43.5 1.12 (0.83–1.52) 0.45 1.19 (0.82–1.72) 0.34 1.10 (0.91–1.33) 0.3
rs889312 MAP3K1 A/C 35.1 28.9 1.37 (1.03–1.81) 0.02 1.74 (1.08–2.82) 0.01 1.33 (1.09–1.63) 0.003
rs3817198 LSP1 T/C 32.1 28.4 1.15 (0.87–1.52) 0.3 1.45 (0.90–2.34) 0.1 1.19 (0.97–1.46) 0.08
rs13387042 2q35 A/G 41.6 44.8 0.92 (0.68–1.25) 0.5 0.76 (0.52–1.12) 0.15 0.88 (0.73–1.06) 0.16
rs13281615 8q24 A/G 55.2 50.4 1.19 (0.85–1.66) 0.3 1.44 (0.99–2.10) 0.04 1.21 (1.00–1.46) 0.03
CI confidence interval, OR odds ratio, HetOR odds ratio in heterozygote, HomOR odds ratio in homozygote for risk allele (relative to
homozygote for non-risk allele)
a Reference allele/risk allele
b Also known as TOX3
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OR = 2.15, P = 0.001, for heterozygous and homozygous
variant genotypes, respectively) (Supplementary Table 4).
On the other hand, homozygous variant genotype of
rs8051542 in the TNRC9 gene was found to be associated
with an increased risk of both ER? and ER- tumors with the
same extent (OR = 2.38, P = 0.0005, OR = 2.35,
P = 0.0007 for ER? and ER-, respectively) (Supplemen-
tary Table 4). FGFR2 rs2981582 and TNRC9 rs8051542
polymorphisms were also associated with both PR? and
PR- tumors, while rs889312 in the MAP3K1 gene was only
associated with PR? tumors (OR = 2.07, P = 0.01) (Sup-
plementary Table 5). The rs13281615 SNP on 8q24 was
Table 3 Associations between GWAS breast cancer loci and lymph node involvement
SNP Controls No cases Yes cases No vs. Yes
OR (95 %CI)
P value Controls vs. No
OR (95 %CI)
P value Controls vs. Yes
OR (95 %CI)
P value
rs1219648
AA 146 62 111 1 1 1
AG 153 113 183 0.90 (0.60–1.36) 0.6 1.74 (1.16–2.60) 0.004 1.57 (1.12–2.21) 0.006
GG 61 57 70 0.69 (0.42–1.13) 0.1 2.20 (1.34–3.61) 0.0008 1.51 (0.97–2.36) 0.05
G allele 0.83 (0.65–1.06) 0.1 1.55 (1.22–1.98) 0.0002 1.29 (1.04–1.60) 0.01
rs2981582
GG 140 44 94 1 1 1
AG 154 124 191 0.72 (0.46–1.12) 0.1 2.56 (1.66–3.96) 0.000006* 1.85 (1.30–2.62) 0.0003
AA 64 67 80 0.56 (0.33–0.93) 0.01 3.33 (2.00–5.56) 0.0000006* 1.86 (1.20–2.90) 0.003
A allele 0.76 (0.60–0.97) 0.02 1.87 (1.47–2.39) 0.0000002* 1.43 (1.15–1.77) 0.0008
rs8051542
CC 146 73 127 1 1 1
CT 176 115 150 0.75 (0.51–1.11) 0.1 1.31 (0.89–1.92) 0.1 0.98 (0.70–1.37) 0.9
TT 46 46 86 1.07 (0.66–1.75) 0.75 2.00 (1.18–3.39) 0.005 2.15 (1.37–3.38) 0.0004
T allele 1.00 (0.79–1.28) 0.9 1.38 (1.09–1.77) 0.006 1.39 (1.12–1.73) 0.001
rs12443621
GG 98 69 110 1 1 1
AG 180 117 164 0.88 (0.59–1.31) 0.5 0.92 (0.62–1.38) 0.6 0.81 (0.57–1.16) 0.2
AA 85 48 92 1.20 (0.74–1.96) 0.43 0.80 (0.49–1.32) 0.3 0.96 (0.63–1.47) 0.8
rs3803662
CC 126 76 114 1 1 1
TC 165 102 169 1.10 (0.74–1.65) 0.6 1.02 (0.69–1.52) 0.8 1.13 (0.80–1.60) 0.4
TT 78 57 84 0.98 (0.61–1.57) 0.9 1.21 (0.76–1.94) 0.3 1.19 (0.78–1.81) 0.3
rs889312
AA 187 106 146 1 1 1
AC 151 97 178 1.33 (0.92–1.92) 0.1 1.13 (0.79–1.63) 0.4 1.51 (1.10–2.08) 0.008
CC 31 32 42 0.95 (0.55–1.66) 0.8 1.82 (1.02–3.27) 0.03 1.74 (1.01–2.99) 0.03
C allele 1.07 (0.83–1.37) 0.5 1.28 (0.99–1.66) 0.04 1.37 (1.10–1.72) 0.004
rs3817198
TT 192 111 172 1 1 1
CT 147 96 157 1.06 (0.73–1.52) 0.7 1.13 (0.79–1.62) 0.4 1.19 (0.87–1.64) 0.2
CC 32 28 38 0.88 (0.49–1.56) 0.6 1.51 (0.83–2.74) 0.1 1.33 (0.77–2.29) 0.2
rs13387042
AA 115 84 118 1 1 1
AG 175 107 183 1.22 (0.83–1.79) 0.2 0.84 (0.57–1.23) 0.3 1.02 (0.72–1.44) 0.9
GG 77 44 65 1.05 (0.64–1.74) 0.8 0.78 (0.48–1.28) 0.3 0.82 (0.53–1.28) 0.3
rs13281615
AA 93 45 81 1 1 1
AG 176 116 165 0.79 (0.50–1.25) 0.2 1.36 (0.87–2.13) 0.1 1.08 (0.73–1.58) 0.6
GG 96 74 120 0.90 (0.55–1.47) 0.6 1.59 (0.97–2.61) 0.05 1.44 (0.94–2.19) 0.07
*P value \ 0.0001 (cut-off for correction)
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found to be associated with ER? and PR- tumors (Sup-
plementary Table 4 and 5).
Regarding disease progression, it was noted that FGFR2
rs2981582 and rs1219648, TNRC9 rs8051542, and MAP3K1
rs889312 polymorphisms were associated with increased
risk of distant metastasis development (Table 4). The
strongest association was found with the minor allele of
FGFR2 rs2981582 in a dose-dependant manner (OR =
2.30, P = 0.004, OR = 3.57, P = 0.00006) (Table 4). For
rs13387042 on 2q35, GG genotype was more frequent in
Table 4 Associations between GWAS breast cancer loci and distant metastasis
SNP Controls No cases Yes cases No vs. Yes
OR (95 %CI)
P value Controls vs. No
OR (95 %CI)
P value Controls vs. Yes
OR (95 %CI)
P value
rs1219648
AA 146 154 30 1 1 1
AG 153 266 44 0.85 (0.50–1.45) 0.5 1.65 (1.21–2.25) 0.001 1.40 (0.81–2.42) 0.2
GG 61 106 24 1.16 (0.62–2.18) 0.6 1.65 (1.10–2.47) 0.01 1.91 (0.99–3.70) 0.03
G allele 1.06 (0.77–1.46) 0.6 1.35 (1.11–1.64) 0.002 1.43 (1.03–1.99) 0.02
rs2981582
GG 140 129 19 1 1 1
AG 154 281 48 1.16 (0.63–2.14) 0.6 1.98 (1.44–2.73) 0.00001* 2.30 (1.24–4.27) 0.004
AA 64 120 31 1.75 (0.90–3.43) 0.07 2.03 (1.36–3.05) 0.0002 3.57 (1.79–7.15) 0.00006*
A allele 1.32 (0.96–1.82) 0.07 1.49 (1.22–1.81) 0.00004* 1.97 (1.41–2.74) 0.00002*
rs8051542
CC 146 169 37 1 1 1
CT 176 251 32 0.58 (0.34–1.00) 0.03 1.23 (0.91–1.67) 0.1 0.72 (0.41–1.25) 0.2
TT 46 108 28 1.18 (0.66–2.12) 0.5 2.03 (1.32–3.12) 0.0006 2.40 (1.27–4.53) 0.003
T allele 1.05 (0.76–1.44) 0.7 1.38 (1.14–1.69) 0.0009 1.45 (1.04–2.02) 0.02
rs12443621
GG 98 150 37 1 1 1
AG 180 256 39 0.62 (0.37–1.04) 0.05 0.93 (0.67–1.29) 0.6 0.57 (0.33–0.99) 0.03
AA 85 123 23 0.76 (0.41–1.39) 0.3 0.95 (0.64–1.40) 0.7 0.72 (0.38–1.35) 0.2
rs3803662
CC 126 172 27 1 1 1
TC 165 238 48 1.28 (0.75–2.21) 0.3 1.06 (0.77–1.45) 0.7 1.36 (0.78–2.38) 0.2
TT 78 121 24 1.26 (0.67–2.39) 0.4 1.14 (0.78–1.67) 0.4 1.44 (0.74–2.79) 0.2
rs889312
AA 187 232 32 1 1 1
AC 151 237 54 1.65 (1.00–2.73) 0.03 1.27 (0.95–1.69) 0.1 2.09 (1.25–3.50) 0.002
CC 31 61 13 1.55 (0.72–3.28) 0.2 1.59 (0.96–2.62) 0.05 2.45 (1.08–5.50) 0.01
C allele 1.32 (0.96–1.83) 0.07 1.26 (1.02–1.56) 0.02 1.67 (1.19–2.34) 0.001
rs3817198
TT 192 253 45 1 1 1
CT 147 220 45 1.15 (0.72–1.85) 0.5 1.14 (0.85–1.52) 0.3 1.31 (0.80–2.14) 0.2
CC 32 58 9 0.87 (0.37–1.98) 0.7 1.38 (0.84–2.26) 0.1 1.20 (0.49–2.85) 0.6
rs13387042
AA 115 185 28 1 1 1
AG 175 260 46 1.17 (0.68–2.00) 0.5 0.92 (0.68–1.26) 0.6 1.08 (0.62–1.89) 0.7
GG 77 85 25 1.94 (1.03–3.68) 0.02 0.69 (0.46–1.03) 0.05 1.33 (0.69–2.57) 0.3
G allele 1.38 (1.01–1.89) 0.03 0.84 (0.69–1.02) 0.07 1.16 (0.84–1.61) 0.3
rs13281615
AA 93 106 27 1 1 1
AG 176 253 44 0.68 (0.39–1.20) 0.1 1.26 (0.89–1.79) 0.1 0.86 (0.48–1.53) 0.5
GG 96 171 28 0.64 (0.35–1.20) 0.1 1.56 (1.06–2.31) 0.01 1.00 (0.53–1.91) 0.9
* P value \ 0.0001 (cut-off for correction)
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patients developing distant metastasis compared to patients
without distant metastasis (25.2 vs. 16 %) (OR = 1.94,
P = 0.02).
Effects of GWAS risk loci on survival from breast
cancer
In this study, we also assessed the effect of GWAS risk loci
on the OVS of patients. A significant difference was
observed between the OVS Kaplan–Meier survival curves
for rs1219648 in the FGFR2 gene. As shown in Fig. 1a, the
breast cancer-specific OVS rate was significantly higher
among patients carrying the G variant allele. The OVS
rates in the group of patients with or without the rs1219648
G allele were 98.1 versus 92 %, respectively (log-rank test,
P = 0.013). However, no significant difference between
the OVS Kaplan–Meier survival curves was observed for
rs2981582. In addition, significant difference between OVS
Kaplan–Meier curves was observed for rs13387042 on
2q35. The OVS rate was significantly lower in the group of
patients without rs13387042 A allele compared to patients
with rs13387042 A allele (89.9 vs. 97.7 % respectively;
log-rank test, P = 0.005) (Fig. 1b).
Discussion
GWAS have led to the identification of multiple new
genetic variants associated with breast cancer risk. Most of
these breast cancer GWAS and replication studies have
been conducted in European populations [8–10, 12, 14–16,
18] and to a lesser extent in Asians [13, 17, 19]. However,
there are significant differences in allele frequencies and
the prevalence of breast cancer among different popula-
tions. It is, therefore, important to explore the effects of the
GWAS-identified markers in other ethnic populations,
including women of Arab ancestry. Thus, we carried out
this study to estimate the allele frequencies of 9 GWAS-
identified loci in the Tunisian population and to investigate,
with a case–control study, the potential association of these
loci with the risk of breast cancer among Tunisian women.
The 10q26 (FGFR2) locus was discovered in two GWAS
among women of European descent [8, 9] and the index
SNPs rs1219648 and rs2981582 have since been consistently
replicated in European [12, 25] and Chinese populations [26]
as well as in several ethnic groups including Hispanic and
non-Hispanic white women [27] and African American
women [28, 29]. In this study, it was also confirmed that
FGFR2 rs1219648 and rs2981582 were significantly asso-
ciated with increased breast cancer risk in the Tunisian
population, which strengthens the conclusion that this locus
plays an important role in the development of breast cancer.
FGFR2 is a member of the receptor tyrosine kinase family,
involved in mammary gland proliferation and development
[30, 31]. It has been shown that FGFR2 can transform normal
human mammary epithelial cells and is over-expressed in
breast tumors [32]. The two polymorphisms in the FGFR2
gene were originally identified by Hunter et al. [9] and were
associated with risk of sporadic post-menopausal breast
cancer Slattery et al. [27] reported similar findings for post-
menopausal Hispanic women. In this study, we have not
evaluated the risk of breast cancer according to the meno-
pausal status. However, although 53.1 % of our cases were
premenopausal, we found strong associations between both
FGFR2 polymorphisms and breast cancer risk. This may
suggests that in the Tunisian population, SNPs rs1219648
and rs2981582 may confer similar effects in both pre and
post-menopausal women.
Of the 3 SNPs evaluated in the TNRC9 locus, only
rs8051542 replicated breast cancer risk among Tunisian
women. No associations were found with rs3803662 and
rs12443621. The SNP rs3803662 was identified as breast
Fig. 1 The 6-year breast cancer-specific overall survival of 640
breast cancer patients stratified by genotype. Overall survival of 640
patients according to the presence or absence of a rs1219648-G allele
and b rs13387042-A allele (P denotes the log-rank test value)
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cancer susceptibility variant in two GWAS, both conducted
in European populations [8, 10]. This SNP remained the
strongest signal for the 16q12 region in further studies of
European ancestry and has also been confirmed from deep
sequencing study as a key TNRC9 SNP associated with
breast cancer [16, 33]. Zheng et al. [34] found that
rs3803662 was associated with breast cancer risk in a
Southern Chinese population. However, the association
with TNRC9 rs3803662 was not confirmed in other ethnic
groups including Hispanic [27] and African American
women [28, 29, 33, 35]. In this study, we also showed the
lack of association of rs12443621 with risk of breast cancer
among Tunisian women. SNP rs12443621 was identified to
increase breast cancer risk by Easton et al. [8] and was
found to be in strong linkage disequilibrium with SNP
rs3803662 of the TNRC9 gene. In addition, at the 16q12
locus, the LD pattern between rs3803662 and rs3104793
was also different across populations [36]. Taken together,
LD pattern difference across populations may explain the
discrepancy between these studies. Thus, a fine-mapping
study might be an effective approach to identify the causal
variant(s) in the 16q12 locus in Arab women.
In this study, we also found the SNP rs889312 in the
MAP3K1 gene and rs13281615 on 8q24 to be associated
with an increased risk of breast cancer in the Tunisian
population. The rs889312 SNP in the MAP3K1 gene was
identified by Easton et al. and has been shown to be
involved in a potential key pathway for breast cancer [8, 9,
14]. The rs13281615 variant lies in a non-genetic region of
chromosome 8q24. Other independent variants in the
region 8q24 have been associated with the risk of prostate,
colorectal and ovarian cancer [37–39].
Associations with most of the susceptibility loci iden-
tified to date are evidently stronger for ER? than for ER-
disease. The strongest evidence is for a variant in FGFR2
that was primarily associated with ER? disease [12].
Garcia-Closas et al. [40] also confirmed a stronger asso-
ciation between FGFR2 rs2981582 and ER? tumors.
Similarly, FGFR2 rs1219648 and rs2981582 genotypes
were significantly associated with breast cancer in Euro-
pean-American only in ER? and PR? tumors [25]. Find-
ings of Slattery et al. [27] suggest that FGFR2
polymorphisms decrease the likelihood of ER-/PR-
tumors among non-Hispanic white women, while increas-
ing the likelihood of ER?/PR? among Hispanic women.
Our data showed that FGFR2 rs2981582 and TNRC9
rs8051542 were strongly associated with both positive and
negative tumor status of ER and PR receptors.
MAP3K1 variants were found to be relevant in ER? and
PR? tumors to greater degree than in ER negative or PR
negative tumors [40]. Moreover, MAP3K1 rs889312 vari-
ant genotype was associated with larger tumors in Asians
but not in European populations, and less likely to be
associated with lymph node positive at breast cancer
diagnosis in a Dutch population [40, 41]. Rebbeck et al.
[25] showed that the same SNP was associated with breast
cancer in African-American women, but again limited only
to ER?, PR? tumors. Our data showed that homozygous
variant genotype of MAP3K1 rs889312 was associated with
PR? but not with PR- tumors, and while not reaching
significance, was more likely to be associated with ER-
tumors but not with ER? tumors. Moreover, rs889312
homozygous variant genotype seems to be associated with
an increased risk of both small and large tumors and was
equally associated with negative and positive nodal
involvement. Taken together, associations between
MAP3K1 rs889312 and breast cancer characteristics need
to be further explored in other ethnic groups.
Regarding disease progression, we found that
rs13387042 homozygous variant genotype was associated
with distant metastasis. This finding suggested that
rs13387042 variant allele might affect the progression of
breast cancer. The rs13387042 variant lies in a non-genic
region of chromosome 2q35. Thus, functional studies in
this region are likely to lead to a better understanding of
mechanisms of carcinogenesis and progression of breast
cancer.
Two out of the nine SNPs included in this study had a
significant association with the OVS. A higher rate of
survival was observed in patients carrying the variant allele
of rs1219648 in the FGFR2 gene. Conversely, a lower
OVS rate was found in patients carrying homozygous
variant genotype of rs13387042 on 2q35. In the Tunisian
population, homozygous variant genotype of rs1219648
was associated with ER? but not with ER- tumors. The
good prognosis known for ER? tumors could explain the
association found between rs1219648 variant of the
FGFR2 gene and the high rate of survival.
The present association study in the Tunisian population
highlighted genetic susceptibility patterns different from that
reported for other populations. These differences could stem
from disparities in genetic background, including differences
in allele frequencies and LD pattern, and gene–environment
interaction. Moreover, clinical and biological differences in
breast cancer have been found in Arab women compared to
Europeans [42]. Early disease onset and aggressive forms of
breast cancer are seen more frequently in Arab populations
[42]. Breast cancer tumors in Arab populations are frequently
characterized by large tumor size, high histo-pronostic SBR
grade and molecular luminal subtype B [42]. In addition,
apart differences in biological characteristics and genetic
background, Arab populations greatly differ from European
and Asian populations by lifestyle, reproductive behavior,
family history status, and environmental exposure, suggest-
ing that risk factors associated with breast cancer develop-
ment and progression might be different in these different
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populations. The high proportion of young-onset and poor
prognosis of breast cancer in women of Arab ancestry is
probably due to a correspondingly high prevalence of perti-
nent genetic risk factors that may be uniquely associated with
these populations. Thus, new GWAS in women of Arab
ancestry may promise to reveal new causal variants and are
needed to fully uncover the genetic basis for breast cancer
susceptibility in Arab population.
In conclusion, the present association study in the
Tunisian population revealed several implications of the 9
SNPs that had been associated with increased risk of breast
cancer in GWAS. It reinforces the need to replicate the
GWAS discovered variants across different populations
and ethnicities.
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